Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.

Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S.

Cancer Res. 2020 Jan 15;80(2):362. doi: 10.1158/0008-5472.CAN-19-3573. No abstract available.

2.

A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial.

Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young B, Hanusch CA, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S.

Clin Cancer Res. 2020 Jan 13. pii: clincanres.1954.2019. doi: 10.1158/1078-0432.CCR-19-1954. [Epub ahead of print]

PMID:
31932495
3.

Histotype-specific analysis of acid ceramidase expression in ovarian cancer.

El-Balat A, Karn T, Holtrich U, Becker S, Kommoss S, Győrffy B, Anglesio MS, Huntsman DG, Drosos Z, Rody A, Gevensleben H, Hanker LC.

Virchows Arch. 2020 Jan 2. doi: 10.1007/s00428-019-02728-0. [Epub ahead of print]

PMID:
31897818
4.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.

Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.

Breast Cancer Res. 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z.

5.

Modeling a recurrent, hidden dynamical system using energy minimization and kernel density estimates.

Karn TK, Petrone S, Griffin C.

Phys Rev E. 2019 Oct;100(4-1):042137. doi: 10.1103/PhysRevE.100.042137.

PMID:
31770961
6.

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.

Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, Weber K, Lück HJ, Huober J, Karn T, Mackelenbergh MV, Marmé F, Schem C, Stickeler E, Untch M, Müller V.

Br J Cancer. 2019 Dec;121(12):1009-1015. doi: 10.1038/s41416-019-0630-3. Epub 2019 Nov 15.

PMID:
31728025
7.

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.

Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L.

Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.

8.

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial.

Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, Marmé F, Nekljudova V, Schem C, Stickeler E, Willumsen N, Karsdal MA, Untch M, Müller V.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1186. doi: 10.3390/cancers11081186.

9.

Quantitative analysis of the sHLA-G protein in seminal plasma.

Schallmoser A, Raab M, Karn T, Königsberger S, Schmidt E, Breitenbach-Koller H, Sänger N.

Am J Reprod Immunol. 2019 Sep;82(3):e13152. doi: 10.1111/aji.13152. Epub 2019 Jun 10.

PMID:
31132194
10.

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.

Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C.

Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub 2019 May 7.

PMID:
31075727
11.

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.

Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C.

Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.

PMID:
30979740
12.

Correction: The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis (doi:10.1242/jcs.155721).

Keinan O, Kedan A, Gavert N, Selitrennik M, Kim S, Karn T, Becker S, Lev S.

J Cell Sci. 2019 Mar 7;132(5). pii: jcs227868. doi: 10.1242/jcs.227868. No abstract available.

13.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4.

PMID:
30694523
14.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H.

BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

15.

Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva.

Gasimli K, Straussner M, Schmeil I, Karn T, Winkelmann R, Becker S, El-Balat A.

Arch Gynecol Obstet. 2018 Nov;298(5):945-950. doi: 10.1007/s00404-018-4887-1. Epub 2018 Sep 6.

PMID:
30187190
16.

Claudin-1 is linked to presence of implants and micropapillary pattern in serous borderline epithelial tumours of the ovary.

El-Balat A, Schmeil I, Gasimli K, Sänger N, Karn T, Ahr A, Becker S, Arsenic R, Holtrich U, Engels K.

J Clin Pathol. 2018 Dec;71(12):1060-1064. doi: 10.1136/jclinpath-2018-205292. Epub 2018 Aug 31.

PMID:
30171086
17.

Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.

El-Balat A, Schmeil I, Karn T, Holtrich U, Mavrova-Risteska L, Rody A, Youssef A, Hanker LC.

In Vivo. 2018 Sep-Oct;32(5):1275-1281. doi: 10.21873/invivo.11377.

18.

The effect of galvanic vestibular stimulation on path trajectory during a path integration task.

Karn T, Cinelli ME.

Q J Exp Psychol (Hove). 2019 Jun;72(6):1550-1560. doi: 10.1177/1747021818798824. Epub 2018 Sep 17.

PMID:
30131006
19.

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.

Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.

PMID:
29233559
20.

Claudin-1 expression in cervical cancer.

Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, Thill M, Rody A, El-Balat A, Hanker L.

Mol Clin Oncol. 2017 Nov;7(5):880-884. doi: 10.3892/mco.2017.1391. Epub 2017 Aug 25.

21.

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S.

Breast Cancer Res Treat. 2018 Jan;167(1):59-71. doi: 10.1007/s10549-017-4480-5. Epub 2017 Sep 5.

PMID:
28875243
22.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.

PMID:
28822007
23.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.

JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.

24.

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.

JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.

25.

TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

El-Balat A, Schmeil I, Karn T, Becker S, Sänger N, Holtrich U, Arsenic R.

Pathol Oncol Res. 2018 Apr;24(2):277-282. doi: 10.1007/s12253-017-0240-4. Epub 2017 May 3.

PMID:
28470574
26.

Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.

Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L.

Cancer Res. 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478. Epub 2017 Apr 20.

27.

IMP3 Expression in Borderline Tumors of the Ovary.

El-Balat A, Sänger N, Karn T, Becker S, Holtrich U, Muallem Z, Arsenic R.

Anticancer Res. 2017 Feb;37(2):583-588.

PMID:
28179304
28.

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.

Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S.

Cancer Res. 2017 Jan 1;77(1):86-99. doi: 10.1158/0008-5472.CAN-16-1797. Epub 2016 Oct 28. Erratum in: Cancer Res. 2020 Jan 15;80(2):362.

29.

Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.

Hoellen F, Kostara A, Karn T, Holtrich U, El-Balat A, Otto M, Rody A, Hanker LC.

Mol Clin Oncol. 2016 Oct;5(4):422-428. Epub 2016 Aug 17.

30.

New Strategies in Breast Cancer: Immunotherapy.

Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G.

Clin Cancer Res. 2016 May 1;22(9):2105-10. doi: 10.1158/1078-0432.CCR-15-1315. Epub 2016 Feb 11.

31.

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer.

Karn T, Rody A, Müller V, Schmidt M, Becker S, Holtrich U, Pusztai L.

Genom Data. 2014 Oct 23;2:354-6. doi: 10.1016/j.gdata.2014.09.014. eCollection 2014 Dec.

32.

The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.

Karn T, Pusztai L, Rody A, Holtrich U, Becker S.

Curr Cancer Drug Targets. 2015;15(8):652-64. Review.

PMID:
26452382
33.

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.

Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G.

Clin Cancer Res. 2016 Jan 15;22(2):337-45. doi: 10.1158/1078-0432.CCR-15-0757. Epub 2015 Sep 30.

34.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J.

Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

35.

Fascin-1 expression as stratification marker in borderline epithelial tumours of the ovary.

El-Balat A, Arsenic R, Sänger N, Karn T, Becker S, Holtrich U, Engels K.

J Clin Pathol. 2016 Feb;69(2):142-8. doi: 10.1136/jclinpath-2015-203224. Epub 2015 Sep 11.

PMID:
26362828
36.

The prognostic impact of age in different molecular subtypes of breast cancer.

Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S, Karn T.

Breast Cancer Res Treat. 2015 Aug;152(3):667-73. doi: 10.1007/s10549-015-3491-3. Epub 2015 Jul 21.

PMID:
26195120
37.

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C.

Breast Cancer Res Treat. 2015 Feb;149(3):789-97. doi: 10.1007/s10549-015-3277-7. Epub 2015 Feb 5.

PMID:
25651779
38.

PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition.

Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S.

Nat Commun. 2015 Feb 4;6:6064. doi: 10.1038/ncomms7064.

PMID:
25648557
39.

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V.

Onco Targets Ther. 2014 Nov 28;7:2205-13. doi: 10.2147/OTT.S65344. eCollection 2014.

40.

Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Sänger N, Engels K, Graf A, Ruckhäberle E, Effenberger KE, Fehm T, Holtrich U, Becker S, Karn T.

Geburtshilfe Frauenheilkd. 2014 Nov;74(11):1016-1022.

41.

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G.

Ann Oncol. 2015 Jan;26(1):95-100. doi: 10.1093/annonc/mdu487. Epub 2014 Oct 29.

42.

Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer.

Győrffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L.

Int J Cancer. 2015 May 1;136(9):2091-8. doi: 10.1002/ijc.29247. Epub 2014 Oct 11.

43.

The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis.

Keinan O, Kedan A, Gavert N, Selitrennik M, Kim S, Karn T, Becker S, Lev S.

J Cell Sci. 2014 Nov 1;127(Pt 21):4740-9. doi: 10.1242/jcs.155721. Epub 2014 Sep 1. Erratum in: J Cell Sci. 2019 Mar 7;132(5):.

44.

Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer.

Sänger N, Ruckhäberle E, Györffy B, Engels K, Heinrich T, Fehm T, Graf A, Holtrich U, Becker S, Karn T.

Mol Oncol. 2015 Jan;9(1):58-67. doi: 10.1016/j.molonc.2014.07.016. Epub 2014 Jul 31.

45.

OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.

Sänger N, Ruckhäberle E, Bianchini G, Heinrich T, Milde-Langosch K, Müller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S, Karn T.

Mol Oncol. 2014 Oct;8(7):1196-207. doi: 10.1016/j.molonc.2014.04.003. Epub 2014 Apr 15.

46.

Prognostic relevance of glycosylation-associated genes in breast cancer.

Milde-Langosch K, Karn T, Schmidt M, zu Eulenburg C, Oliveira-Ferrer L, Wirtz RM, Schumacher U, Witzel I, Schütze D, Müller V.

Breast Cancer Res Treat. 2014 Jun;145(2):295-305. doi: 10.1007/s10549-014-2949-z. Epub 2014 Apr 16.

PMID:
24737166
47.

High-throughput gene expression and mutation profiling: current methods and future perspectives.

Karn T.

Breast Care (Basel). 2013 Dec;8(6):401-6. doi: 10.1159/000357461. Review.

48.

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Müller V, Schmidt S, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L.

Breast Cancer Res. 2013;15(5):R86.

49.

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9. doi: 10.1007/s00432-013-1490-5. Epub 2013 Aug 18.

PMID:
23955546
50.

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.

von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching PA, Karn T, Müller V, Jackisch C, Denkert C.

Clin Cancer Res. 2013 Aug 15;19(16):4521-31. doi: 10.1158/1078-0432.CCR-12-3628. Epub 2013 Jun 27.

Supplemental Content

Support Center